Cagri peptide, or cagrilintide, is a long-acting amylin analog studied for weight loss. Learn how it works, its side effects, and whether it's FDA-approved.
“Cagri peptide” is the common shorthand for cagrilintide, a long-acting synthetic version of amylin — a hormone your pancreas releases alongside insulin after you eat. Cagrilintide is not a GLP-1 drug like semaglutide or tirzepatide; it works mainly through amylin and calcitonin receptors to slow stomach emptying and increase feelings of fullness. It remains investigational in the United States and is not FDA-approved for weight loss, diabetes, or any other human use.
What Is Cagrilintide and How Does It Work?
Searches for “what is cagri” climbed sharply after Novo Nordisk reported phase 3 results for CagriSema, a combination of cagrilintide and semaglutide. The weight-loss numbers were large enough to draw attention from people who had already tried GLP-1 medications and wanted to know what else existed.
Amylin is a natural companion to insulin. After a meal, it helps you feel full, slows the rate at which food leaves your stomach, and blunts the post-meal rise in glucagon. People living with obesity often show altered amylin signaling, which is why researchers began modifying the hormone into something longer-lasting.
Cagrilintide is that modification. A fatty acid chain attached to the molecule lets it bind to albumin in the blood, which slows breakdown and stretches its half-life to roughly seven to eight days — long enough for once-weekly injection.
- Slower gastric emptying: food stays in the stomach longer, extending fullness after meals.
- Central satiety signaling: amylin receptors in the hindbrain reduce the drive to eat.
- Lower glucagon: less glucagon release means less glucose pushed into the bloodstream between meals.
- No direct GLP-1 activity: cagrilintide does not activate GLP-1 receptors on its own.
Because these mechanisms stack rather than duplicate each other, combining cagrilintide with a GLP-1 produces more appetite suppression than either peptide alone.
Cagri Peptide Benefits Reported in Clinical Trials
The most talked-about cagri peptide benefits come from the REDEFINE clinical program. The results are promising, but they come from controlled research settings rather than consumer use.
- In a phase 2 monotherapy trial, cagrilintide alone produced up to about 10.8% average weight loss over 26 weeks at the highest dose tested.
- In REDEFINE 1, adults without diabetes taking CagriSema lost an average of roughly 20.4% of body weight at 68 weeks, with treatment completers averaging closer to 22.7%.
- REDEFINE 2 tested the same combination in people with type 2 diabetes and excess weight, showing meaningful reductions in both weight and A1C.
Early data also pointed to improvements in blood pressure and lipid markers, though those were secondary outcomes. No trial has shown that cagrilintide reverses, treats, or cures any disease on its own.
Cagri Peptide Dosage and Dosing Schedule
There is no official cagri peptide dosage for human use, because no regulatory agency has approved the drug. Everything published comes from investigational protocols.
In trials, cagrilintide was given as a once-weekly subcutaneous injection, starting low and escalating every few weeks to limit nausea. Monotherapy doses ranged from 0.6 mg up to 4.5 mg per week, while CagriSema arms used fixed combinations such as 2.4 mg cagrilintide with 2.4 mg semaglutide.
Anyone using unapproved cagrilintide outside a trial is dosing without safety data, quality control, or medical supervision — a meaningfully different situation from trial participants.
Cagri Peptide Side Effects and Safety
The most frequently reported cagri peptide side effects are gastrointestinal. They are usually mild to moderate and often ease as the body adjusts, but they remain the leading reason participants stop treatment.
- Nausea, vomiting, and diarrhea
- Constipation and reduced appetite
- Injection-site reactions such as redness or swelling
- Fatigue and headache
Less common but more serious concerns include gallbladder disease, pancreatitis, and low blood sugar when the peptide is combined with insulin or sulfonylureas. Cagrilintide has not been studied in pregnancy or in children.
Because unapproved peptides sold online are not guaranteed to contain what the label claims, contamination and dosing errors are real risks. Speak with a healthcare professional before considering any injectable peptide.
Cagri Peptide vs Tirzepatide: Key Differences
The cagri peptide vs tirzepatide comparison comes up constantly because both are injectable peptides studied for weight loss, yet they belong to different drug classes. Tirzepatide activates GLP-1 and GIP receptors; cagrilintide targets amylin and calcitonin receptors.
| Feature | Cagrilintide (cagri peptide) | Semaglutide | Tirzepatide |
|---|---|---|---|
| Receptor targets | Amylin / calcitonin | GLP-1 | GLP-1 + GIP |
| Dosing | Once weekly (investigational) | Once weekly | Once weekly |
| Trial weight loss | ~10.8% alone; ~20.4% with semaglutide at 68 weeks | ~15% at 68 weeks | ~21% at 72 weeks |
| FDA status | Not approved | Approved for obesity and type 2 diabetes | Approved for obesity and type 2 diabetes |
Those weight-loss percentages come from separate trials with different populations, so they should be read cautiously rather than as head-to-head evidence.
Buying Cagri Peptide: What to Know First
Cagrilintide searches often lead to websites selling lyophilized powder labeled “for research use only.” Those products are not approved for human consumption, and their purity and sterility are not verified by the FDA.
The same communities that ask what is bpc 157 peptide also trade notes on cagrilintide, but that shared interest does not make either supply chain safer. Vials can be underdosed, overdosed, or contaminated, and there is no reliable way to test them at home.
The supervised route is a prescription through a licensed clinician — currently limited to approved drugs such as semaglutide and tirzepatide, since cagrilintide is still in trials.
The bottom line: Cagrilintide is a genuine scientific advance in the amylin field and one of the most closely watched obesity drugs in development. Cagri peptide is not FDA-approved for human use in the United States, and no dose, benefit, or side effect profile has been confirmed outside clinical research. If you are considering an amylin-based treatment, ask a doctor about approved options or clinical trial enrollment instead of buying unverified powder online.
Frequently Asked Questions
Is cagri peptide FDA-approved?
No. Cagrilintide has not been approved by the FDA for any indication, including weight loss and type 2 diabetes. It remains an investigational drug while the manufacturer pursues regulatory review. Approved alternatives currently include semaglutide and tirzepatide.
What is cagri peptide used for?
Researchers are studying cagrilintide for chronic weight management and type 2 diabetes, most often combined with semaglutide as CagriSema. Because it is not approved, there is no legitimate consumer use for it today. Vials sold online are marketed as research chemicals, not medicine.
How does cagri peptide compare to Ozempic?
Ozempic is semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes and weight management. Cagrilintide is an amylin and calcitonin receptor agonist that is not approved. The two work through different receptors, which is why researchers are testing them together rather than as substitutes.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.